ReviewPharmaceutics2021
Recent Advances in Liposomal-Based Anti-Inflammatory Therapy.
Review in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Liposomes from red betel (Open veterinary journal · 2025Pooled it
- Polyphenol-Loaded Liposomal Nanocarriers fromMolecules (Basel, Switzerland) · 2026Article
- Nanotechnology-driven delivery of dexamethasone for arthritis: The role of liposomes.EXCLI journal · 2026Review
- Nanoparticle-based approaches for vascular inflammation in managing hypertension: advancing molecular mechanisms and treatment strategies.Drug delivery and translational research · 2026Review
- Targeted nanoliposomes for precision rheumatoid arthritis therapy: a review on mechanisms andDrug delivery · 2025Review
- Poloxamer-Driven Drug Delivery System for Anti-Inflammatory Drugs Using Small-Angle Neutron Scattering Approach.Gels (Basel, Switzerland) · 2025Article
- Ocular drug delivery systems based on nanotechnology: a comprehensive review for the treatment of eye diseases.Discover nano · 2025Review
- Insights into Liposomal and Gel-Based Formulations for Dermatological Treatments.Gels (Basel, Switzerland) · 2025Review
- Liposomal Formulations: A Recent Update.Pharmaceutics · 2024Review
- Comparative In Vitro Study between Biocompatible Chitosan-Based Magnetic Nanocapsules and Liposome Formulations with Potential Application in Anti-Inflammatory Therapy.International journal of molecular sciences · 2024Article
- Challenges in Optimizing Nanoplatforms Used for Local and Systemic Delivery in the Oral Cavity.Pharmaceutics · 2024Review
- Effects of solid lipid nanocarrier containing methyl urolithin A by coating folate-bound chitosan and evaluation of its anti-cancer activity.BMC biotechnology · 2024Article
- A cutting-edge new framework for the pain management in children: nanotechnology.Frontiers in molecular neuroscience · 2024Review
- Current status of immunological therapies for rheumatoid arthritis with a focus on antigen-specific therapeutic vaccines.Frontiers in immunology · 2024Review
- Lipid Nano-System Based Topical Drug Delivery for Management of Rheumatoid Arthritis: An Overview.Advanced pharmaceutical bulletin · 2023Review
- Nanomedicines: intervention in inflammatory pathways of cancer.Inflammopharmacology · 2023Review
- MiR-182-3p targets TRF2 and impairs tumor growth of triple-negative breast cancer.EMBO molecular medicine · 2023Article
- Current Strategies and Potential Prospects for Nanoparticle-Mediated Treatment of Diabetic Nephropathy.Diabetes, metabolic syndrome and obesity : targets and therapy · 2022Review
- Article
- Principles of Biocompatible Nanotube Design for High-Performance Biomaterials.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
Abstract
Liposomes can be seen as ideal carriers for anti-inflammatory drugs as their ability to (passively) target sites of inflammation and release their content to inflammatory target cells enables them to increase local efficacy with only limited systemic exposure and adverse effects. Nonetheless, few liposomal formulations seem to reach the clinic. The current review provides an overview of the more recent innovations in liposomal treatment of rheumatoid arthritis, psoriasis, vascular inflammation, and transplantation. Cutting edge developments include the liposomal delivery of gene and RNA therapeutics and the use of hybrid systems where several liposomal bilayer features, or several drugs, are combined in a single formulation. The majority of the articles reviewed here focus on preclinical animal studies where proof-of-principle of an improved efficacy-safety ratio is observed when using liposomal formulations. A few clinical studies are included as well, which brings us to a discussion about the challenges of clinical translation of liposomal nanomedicines in the field of inflammatory diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.